Skip to main content
PharmacoEconomics Open logoLink to PharmacoEconomics Open
. 2025 Dec 4;10(2):317–329. doi: 10.1007/s41669-025-00623-w

Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A

Li Yang 1, Jie Peng 2, Congling Gu 3, Zhenguo Wang 3, Genyong Zuo 4,✉
PMCID: PMC13000034  PMID: 41343010

Abstract

Background/Objectives

Inhibitor development against recombinant factor VIII (rFVIII) is a significant complication in the prophylactic treatment of severe hemophilia A. The economic impact of varying inhibitor risks among rFVIII products is unclear. We compare the cost effectiveness of two rFVIII products with different incidences of inhibitor development (antihemophilic factor [recombinant], plasma/albumin-free method [rAHF-PFM] vs BAY 81-8973) for prophylaxis in Chinese previously untreated patients (PUPs) with severe hemophilia A.

Methods

From a Chinese healthcare system perspective, a Markov model simulated the lifetime outcomes (inhibitors, bleeding, complications) for PUPs with severe hemophilia A receiving lifetime prophylactic treatment with rAHF-PFM or BAY 81-8973 (incidence of inhibitor development: 30.3% vs 54.8%). Data were sourced from literature, clinical experts, and public sources. Cost effectiveness was assessed using base-case, one-way sensitivity, and probabilistic sensitivity analysis (PSA).

Results

The base-case analysis indicated that rAHF-PFM extended survival by 0.055 years (17.965 vs 17.910) and increased quality-adjusted life years (QALYs) by 0.779 QALYs (9.290 vs 8.511), while saving Chinese Yuan (CNY) 4,578,403 (CNY 12,060,222 vs CNY 16,638,625) compared with BAY 81-8973 in PUPs with severe hemophilia A. Results were most sensitive to the annualized bleeding rate and utility of patients free of bleeding episodes. PSA with 5000 Monte Carlo simulations estimated a 97.5% probability that rAHF-PFM was the cost-effective option.

Conclusions

Prophylactic treatment with rAHF-PFM is likely more cost effective than BAY 81-8973 for Chinese PUPs with severe hemophilia A. This finding is primarily driven by the lower incidence of inhibitor development and fewer bleeding episodes associated with rAHF-PFM in the model.

Supplementary Information

The online version contains supplementary material available at 10.1007/s41669-025-00623-w.

Key Points for Decision Makers

In patients with severe hemophilia A, the development of inhibitors to recombinant factor VIII (rFVIII) therapy can lead to more frequent bleeding episodes, thereby increasing treatment complexity and costs.
From a Chinese healthcare system perspective and over a lifetime horizon, rAHF-PFM, a recombinant factor VIII, could be more cost effective than another recombinant factor VIII (BAY 81-8973) in the prophylactic treatment of severe hemophilia A due to its lower inhibitor development rate.
Future real-world studies are needed to confirm the cost effectiveness of recombinant factor VIII for prophylactic treatment of severe hemophilia A to inform both clinical and reimbursement decision making.

Introduction

Hemophilia A is a hereditary bleeding disorder caused by mutations in the coagulation factor VIII (FVIII) gene, with approximately 49.7% of affected patients experiencing severe forms of the disease [1]. The development of recombinant FVIII (rFVIII) is a cornerstone in the treatment of hemophilia A. Despite the effectiveness of rFVIII, the development of inhibitors can neutralize the activity of the infused rFVIII. This occurs in approximately 20–30% of previously untreated patients (PUPs) with severe hemophilia A who have a complete lack of endogenous factor VIII due to large deletions, nonsense mutations, or inversions in the F8 gene [2, 3]. Their immune system is more likely to recognize rFVIII as a foreign protein and develop antibodies [4]. The presence of inhibitors complicates treatment, making it less effective and necessitating other therapies such as immune tolerance induction (ITI) or the use of bypassing agents [5].

Several recombinant FVIII products have been approved to treat hemophilia A in China. Even though these recombinant FVIII products are designed to mimic the structure and function of natural FVIII, the differences in production methods could substantially affect their immunogenicity and pharmacokinetics, which are highly correlated with the risk of developing inhibitors and the effectiveness of bleeding control [6]. A critical manufacturing difference that may influence immunogenicity is the host cell line used for production, as this determines the protein's post-translational modifications, particularly glycosylation [7]. rAHF-PFM is produced in Chinese Hamster Ovary (CHO) cells, whereas BAY 81-8973 is produced in Baby Hamster Kidney (BHK) cells. This difference in host cells is hypothesized to influence immunogenicity via distinct glycosylation patterns; indeed, evidence suggests that BHK-derived FVIII is more immunogenic than CHO-derived FVIII and exhibits different N-linked glycan profiles [8]. This molecular hypothesis is consistent with clinical findings. In a multicenter study involving 82 PUPs with severe hemophilia A treated with rAHF-PFM, the overall inhibitor development rate was reported to be approximately 24.4% [9], which was substantially lower than that for BAY 81-8973 (54.8%) [10].

The development of inhibitors to rFVIII in patients with hemophilia A is expected to have profound negative impacts on long-term health outcomes and costs. This is because inhibitors reduce the bleeding control effects of rFVIII, subsequently increasing the risk of significant complications associated with bleeding (such as joint damage and life-threatening bleeds) [11]. However, these negative impacts have not been well clarified and are rarely considered in previously published cost-effectiveness analyses. Therefore, this study aimed to compare the cost effectiveness of prophylactic treatment with rAHF-PFM versus BAY 81-8973, two rFVIII products with substantially different inhibitor development profiles, in order to explore how such differences influence lifetime health benefits and economic outcomes in PUPs with severe hemophilia A.

Methods

This study developed a cost-effectiveness analysis (CEA) model from a Chinese healthcare system perspective to simulate the lifetime health outcomes and direct medical costs associated with two rFVIII products with different inhibitor profiles (rAHF-PFM vs BAY 81-8973) for prophylactic treatment of PUPs with severe hemophilia A in China. We conducted a systematic literature review, surveyed clinical experts in the field of hemophilia, and leveraged any relevant public information for the development of the decision analytic model.

Model Structure

Based on the literature evidence, the occurrence of inhibitors with rFVIII products is mainly concentrated in PUPs with severe hemophilia A. Thus, the model cohort was defined as a cohort of PUPs with severe hemophilia A in China. The decision analytic model was constructed to simulate the model cohort for the development of inhibitors, the management of developed inhibitors, and occurrence of bleeding episodes and bleeding-related complications over a lifetime under prophylactic treatment with rAHF-PFM and BAY 81-8973, respectively. The overall structure of this CEA model is illustrated in Fig. 1a.

Fig. 1.

Fig. 1

The structure of the constructed cost-effectiveness model assessing rAHF-PFM relative to BAY 81-8973 for previously untreated patients with severe hemophilia A in China. a Overall structure of CEA model; b decision-making tree model for inhibitor management over 3 years; c Markov model for bleeding episodes and bleeding-related complications). HTI high-titer inhibitors, LTI low-titer inhibitors

To align with the reported incidence of inhibitors in clinical settings, this model assumed that inhibitors only developed in the first year of prophylactic treatment with rFVIII. The model further classified the patients with developed inhibitors into low-titer inhibitors (LTI) and high-titer inhibitors (HTI) for inhibitor eradication treatments. High-dose rFVIII was used to treat patients with LTI for 1 year to eradicate inhibitors. ITI was used to treat patients with HTI for 3 years to eradicate inhibitors. Patients with successful inhibitor eradication treatments continued the prophylactic treatments with the two rFVIIIs in the model. Patients without successful inhibitor eradication treatments received prophylactic treatment with emicizumab or on-demand therapy with bypassing agents for bleeding. The model structure for the management of developed inhibitors is illustrated in Fig. 1b.

A Markov model design was used to simulate the bleeding episodes associated with prophylactic treatments and the bleeding-related complications (hemophilic arthropathy, intracranial hemorrhage [ICH], and gastrointestinal [GI] bleeding) over a lifetime in patients without inhibitor development and the patients receiving inhibitor management. The Markov modeling approach was selected over a partitioned survival model, as the latter is generally more suitable for oncology, where progression through distinct health states can be clearly modeled with survival curves. For chronic conditions like hemophilia A, where disease progression is more gradual and stochastic, a state-transition Markov model is more appropriate for capturing the long-term dynamics of disease, treatment impact, and costs [12]. We classified the bleeding-related complications by time (the first year and subsequent year) to simulate the impact of time on the quality of life and medical costs associated with complications. The cycle length for this Markov model was set to 1 year to align with the chronic nature of hemophilia, which requires lifetime treatment with FVIII. The structure of this Markov model is illustrated in Figure 1c. Death was simulated for all health states in the CEA model to estimate overall survival. The model integrated the quality of life and direct medical costs associated with the health states to estimate quality-adjusted life years (QALYs) and lifetime direct medical costs. The simulated health benefits and costs were discounted at 5% per year to follow the China Pharmacoeconomic Evaluation Guideline [13].

Model Inputs

Clinical Data

This study searched major English (MEDLINE, Embase, Web of Science, and the Cochrane Library) and Chinese (CNKI, WANFANG, and VIP) bibliographic databases from 2013 to 2023 to identify appropriate evidence for estimating model inputs. The literature review process used to identify appropriate evidence for estimating model inputs is detailed in the electronic supplementary material (ESM). The literature search strategies were developed under the guidance of the definition of model inputs. In our study, single-arm meta-analyses were conducted to pool data of the same outcome (e.g., annualized bleeding rate [ABR], inhibitor development rate) reported for the same study arm across multiple studies. The statistical pooling was performed using a random-effects model with the DerSimonian and Laird method to account for potential heterogeneity across studies [14]. This approach was chosen to reflect the underlying clinical and methodological variability that may exist between studies. Between-study heterogeneity was assessed using the I2 statistic, with I2 values of 25%, 50%, and 75% considered to represent low, moderate, and high heterogeneity, respectively. In cases of substantial heterogeneity (I2 > 50%), we conducted sensitivity analyses by excluding outlier studies or subgroup analyses based on patient characteristics, study design, or treatment regimens, where feasible. A weighted mean was used to pool the evidence that couldn’t be synthesized using meta-analysis (e.g., lack of standard deviation for continuous outcomes), using the sample size of each individual study as the weight for its reported outcome. More specifically, the identified literature evidence was used to estimate the demographics of the model cohort, treatment patterns, and treatment outcomes of prophylactic treatment with the two rFVIIIs and emicizumab, inhibitor eradication treatments, and on-demand therapy with bypassing agents, the relationship between the ABR and the risks of the three included complications in the model, and the annual risk of mortality associated with the health states. The direct quantitative relationship between ABR and incremental risks of complications was established from a prospective cohort study investigating the risk of bleeding-related complications over time in patients with hemophilia A [15]. Based on the assumption for the exponential distribution for the reported bleeding-related complications in this study, each additional bleeding episode increase in ABR increased the annual risk of arthropathy by 0.046, of GI bleeding by 0.001, and of ICH by 0.003. In addition, we applied the age-stratified baseline risk of ICH in the Chinese male population to the model to adjust the impact of age on risk of ICH over lifetime simulation in the model [16].

Utility

The quality-of-life utility ratios of model health states relative to the age- and gender-matched Chinese general population were derived from one study assessing quality of life in the classified patients with hemophilia by their ABR [18]. For patients with bleeding-related complications, we applied a utility ratio of 0.439, based on published utility data in Chinese hemophilia patients [17]. This value was applied for the first year of complication, and—based on expert interviews (see Section 2.2.3 for details)—was also extended to subsequent years for hemophilic arthropathy and intracranial hemorrhage, due to their long-term disabling impact. For GI bleeding, utility was assumed to return to the baseline level after 1 year. For patients without complications, utility values were calculated as a function of ABR. Specifically, when ABR was < 5, the reported linear relationship between ABR and utility values in a European cohort (CHESS II) [18] was used to estimate utility by ABR, where utility = 0.898 − 0.061 × ABR; when ABR was ≥ 5, utility was capped at 0.552, based on the observed utility plateau in CHESS II. The utility values were assigned per health state and stratified by complication status and ABR level in the CEA model. If a patient developed a complication, the utility associated with that specific complication took precedence over the ABR-derived utility. All utility data were adjusted using the age-matched Chinese male general population in the model to consider the impact of age on quality of life over lifetime simulation [19].

Cost

The direct medical costs in the model were derived from a combination of public data sources and a formal expert survey. The drug acquisition costs, which constituted a major component of the total cost, were estimated according to treatment dosage, treatment administration frequency, and listed unit prices from public procurement databases in 2024 [20]. For other model inputs where public data were unavailable, a survey of five clinical experts in the field of hemophilia was conducted. This survey gathered data on treatment patterns, including prophylactic and on-demand therapies for patients with and without inhibitors, as well as ITI protocols. It also informed the direct medical costs related to inhibitor development monitoring, bleeding management, and the management of the three bleeding-related complications in the model. To ensure the representativeness of the clinical experts participating in the survey, the five experts were selected from hematology departments of tertiary hospitals or provincial hematology centers in different regions of China, and all had a qualification of associate chief physician or higher. Where multiple expert responses were provided for a single cost input, the average value was used in the model. The medical costs associated with complications (e.g., intracranial hemorrhage, hemophilic arthropathy, gastrointestinal bleeding) were based on the occurrence of specific complications and subsequent management over time. For example, ICH and hemophilic arthropathy incur significant costs in both the first year and in subsequent years, but the model only considered the medical costs in the first year for GI bleeding, which is unlikely to need additional management in the subsequent year. A detailed breakdown of drug acquisition costs and other direct medical costs is provided in Supplementary Tables S5 and S6 (see ESM).

The estimated model inputs are summarized in Table 1.

Table 1.

Summary of the model inputs used in the constructed cost-effectiveness model assessing rAHF-PFM relative to BAY 81-8973 in previously untreated Chinese patients with severe hemophilia A

Variables Baseline Range
95% CI lower limit 95% CI upper limit
Treatment efficacy
 Inhibitor-negative patients
  Incidence of inhibitors, % [9, 10, 22]
   rAHF-PFM 30.3% 13.9% 46.6%
   BAY 81-8973 54.8% 39.7% 69.0%
  Distribution of inhibitor titer levels in rAHF-PFM prophylaxis, % [23–30]
   LTI 44.7%
   HTI 55.3%
  Distribution of inhibitor titer levels in BAY 81-8973 prophylaxis, [10]
   LTI 26.1%
   HTI 73.9%
  Annualized bleeding risk, % [10, 31–38]
   rAHF-PFM prophylaxis 69.2% 59.4% 79.0%
   BAY 81-8973 prophylaxis 73.0% 63.6% 82.4%
  ABR, frequency [10, 30, 36–40]
   rAHF-PFM prophylaxis 3.6 2.4 4.7
   BAY 81-8973 prophylaxis 5.3 3.8 6.8
 Inhibitor-positive patients
  Success rate of inhibitor eradication, %
   LTI patients [41] 94.6% 80.8% 98.6%
   HTI patients [42–51] 78.5% 70.6% 84.8%
  Annual bleeding risk with LTI patients, %
   Post-treatment without successful inhibitor eradication
    On-demand treatment [52, 53] 100.0%
    Emicizumab prophylactic treatment [54, 55] 10.7% 4.1% 17.4%
  Annual bleeding risk with HTI patients, %
   Inhibitor eradication treatment [56] 71.2% 54.6% 83.6%
   Post-treatment without successful inhibitor eradication
    On-demand treatment [52, 53] 100.0%
    Emicizumab prophylactic treatment [53, 57, 58] 46.9% 40.0% 53.8%
  ABR with LTI patients, frequency
   Post-treatment without successful inhibitor eradication
    On-demand treatment [59] 13.1
    Emicizumab prophylactic treatment [53, 57, 58] 3.1
  ABR with HTI patients, frequency
   Inhibitor eradication treatment [50] 4.8 2.7 6.9
   Post treatment without successful inhibitor eradication
    On-demand treatment [53] 37.8
    Emicizumab prophylactic treatment [53, 57, 58] 3.1
Quality of life (ratio of utility values relative to the general population)
 Free of bleeding episode [17] 0.898 0.793 1.000
 The reduced utility ratio per bleeding episode [17, 18] 0.061 0.027 0.096
 ABR of 5 or more [17, 18] 0.552
 Bleeding-related complications [17] 0.439 0.407 0.471
Medical costs (at initial age)
 Annual drug acquisition costs, CNY
  rAHF-PFM prophylaxis ¥310,296
  BAY 81-8973 prophylaxis ¥356,400
  rAHF-PFM hemostasis ¥66,855
BAY 81-8973 hemostasis ¥114,512
  rAHF-PFM high-dose prophylaxis for LTI eradication treatment ¥363,206
  BAY 81-8973 high-dose prophylaxis for LTI eradication treatment ¥417,170
  ITI treatment with rAHF-PFM or pdFVIII for HTI eradication treatment ¥452,932
  ITI treatment with BAY 81-8973 or pdFVIII for HTI eradication treatment ¥506,633

ABR annualized bleeding rate, CNY Chinese Yuan, HTI high-titer inhibitors, ITI immune tolerance induction, LTI low-titer inhibitors, pdFVIII virally inactivated plasma-derived FVIII

Model Assumptions

This study made several assumptions to address the challenges related to model structure and the paucity of literature evidence. These assumptions included the following: (1) the risk of inhibitor development for prophylactic treatment with rFVIII was confined to the first year of treatment; (2) patients who develop inhibitors and succeed in eradication therapy would not develop inhibitors for the subsequent prophylactic treatment with the same rFVIII; (3) patients without bleeding episodes were not susceptible to bleeding-related complications, and those who had experienced complications were not expected to encounter further incidents; (4) the inhibitor eradication treatment was limited to 1 year for patients with LTI and 3 years for patients with HTI.

Data Analysis

This study used statistical software R (version 4.1.0) to synthesize the identified literature evidence and estimate model inputs. Microsoft Excel (version 16.65) was used to construct the decision analytic model and conduct the cost-effectiveness analyses, including the base-case analysis, OWSA (one-way sensitivity analyses) and PSA.

Base-Case Analysis

The model was used to simulate prophylactic treatments with the two rFVIIIs over a lifetime to generate the following model outputs using the baseline point estimations of model inputs: total bleeding episodes, total risk of bleeding-related complications, life years, QALYs, total direct medical costs, and incremental cost-effectiveness ratio (ICER). The model outputs associated with the two rFVIIIs were compared to demonstrate their differences. The baseline model outputs for QALYs and lifetime direct medical costs associated with the two rFVIIIs were used to calculate ICER for prophylactic treatment with rAHF-PFM relative to BAY 81-8973.

Sensitivity Analysis

OWSA were performed by varying each model input from the lower limit to the upper limit of the model input range (95% confidence interval or ± 25% of the baseline value for the model input without a 95% confidence interval) to identify the key model inputs driving the cost effectiveness of rAHF-PFM relative to BAY 81-8973. PSA was conducted using 5000 Monte Carlo simulations, a number considered sufficient for model stabilization [21], from the distributions of model inputs to create the ICER scatter plot for rAHF-PFM relative to BAY 81-8973. The incremental costs and QALYs from the PSA simulations were plotted on a cost-effectiveness plane (ICER scatter plot). The probability that rAHF-PFM was cost effective compared with BAY 81-8973 was determined by the proportion of simulation points falling in the cost-effective region of this plot. The parameters and distributions used for the PSA are summarized in Supplementary Table S7, ESM.

Scenario Analysis

To assess the robustness of the base-case results under different timeframes, scenario analyses were conducted using shorter time horizons. While a lifetime horizon was chosen for the base case to reflect the chronic nature of hemophilia A and the pediatric cohort, we tested the model using alternative horizons of 5, 10, and 20 years. All other model parameters and assumptions remained unchanged from the base-case analysis.

Results

Based on the pooled patient characteristics from observational studies including PUPs with severe hemophilia A from China, the hypothetical model cohort consisted of male patients with a mean age of 8.6 years. This model cohort was applied to conduct simulations and generate the following results.

Lifetime Cumulative Bleeding Episodes and Risk of Bleeding-Related Complications Associated with rAHF-PFM Relative to BAY 81-8973

Based on the pooled incidence of inhibitor development (rAHF-PFM: 30.3%; BAY 81-8973: 54.8%) [9, 10, 22] and distribution of HTI (rAHF-PFM: 55.3%; BAY 81-8973: 73.9%) [10, 23–30] associated with prophylactic treatment with two rFVIIIs, the current inhibitor eradication treatment was able to successfully treat 85.7% of patients with developed inhibitors for rAHF-PFM and 82.7% of patients with developed inhibitors for BAY 81-8973, which were weighted calculations derived from the distribution of HTI and the success rates of inhibitor eradication (LTI: 94.6%; HTI: 78.5%) [41–51]. These differences had a direct impact on the lifetime cumulative bleeding episodes associated with the two rFVIII due to less effective treatments in patients who failed with inhibitor eradication. Based on the lifetime simulation, prophylactic treatment with rAHF-PFM was associated with much lower total bleeding episodes than BAY 81-8973 (198.2 episodes vs 353.4 episodes), mainly through reduced bleeding episodes in patients with inhibitors (66.2 episodes vs 159.2 episodes). Because prophylactic treatment with rAHF-PFM was associated with a lower ABR than BAY 81-8973 (3.6 vs 5.3) [10, 30, 36–40], the lifetime cumulative bleeding episodes associated with rAHF-PFM in patients without developed inhibitors were also lower (132.0 vs 194.2) and further contributed to the overall reduction of bleeding episodes in the patients receiving rAHF-PFM for prophylactic treatment. In addition, rAHF-PFM was associated with a slight reduction of lifetime cumulative risks of bleeding-related complications when compared with BAY 81-8973. The simulated results for the lifetime cumulative bleeding episodes and risks of bleeding related complications from the CEA model are summarized in Table 2.

Table 2.

Summary of the lifetime cumulative bleeding episodes and risks of bleeding complications associated with rAHF-PFM relative to BAY 81-8973 in previously untreated Chinese patients with severe hemophilia A

Prophylactic treatment scenario rAHF-PFM (95% CI) BAY 81-8973 (95% CI) Difference
Lifetime cumulative bleeding episodes
 Total bleeding episodes 198.2 (146.4–255.5) 353.4 (273.0–437.9) − 155.2
 Without inhibitors 132.0 (94.1–175.4) 194.2 (138.1–259.7) − 62.2
 With developed inhibitors 66.2 (31.4–113.6) 159.2 (98.8–231.2) − 93.0
Lifetime cumulative risk of bleeding-related complications
 Intracranial hemorrhage 0.042 (0.041–0.042) 0.043 (0.041–0.042) − 0.001
 Hemophilic arthropathy 0.916 (0.907–0.920) 0.920 (0.16–0.922) − 0.003
 Gastrointestinal bleeding 0.010 (0.010–0.011) 0.011 (0.010–0.011) − 0.001

Base-Case Cost-Effectiveness Analysis

Based on the simulations of discounted overall survival, prophylactic treatment with rAHF-PFM for PUPs with severe hemophilia A could extend life years by 0.055 years (17.965 years vs 17.910 years), increase QALYs by 0.779 (9.290 QALYs vs 8.511 QALYs), and simultaneously reduce lifetime direct medical costs by ¥4,578,403 (¥12,060,222 vs ¥16,638,625) when compared with prophylactic treatment with BAY 81-8973. Further stratifications of these model outputs by patients with different health states suggested that prophylactic treatment with rAHF-PFM gained more QALYs through patients without inhibitor development and reduced direct medical costs on drug acquisition costs for patients who failed with inhibitor eradication. The results of the base-case cost-effectiveness analysis are summarized in Table 3.

Table 3.

Summary of the base-case analysis results in the constructed cost-effectiveness model assessing rAHF-PFM relative to BAY 81-8973 in previously untreated Chinese patients with severe hemophilia A

Prophylactic treatment scenario rAHF-PFM BAY 81-8973 Difference
Total life years 17.965 17.910 0.055
Without inhibitors 12.824 8.622 4.202
With developed inhibitors 5.141 9.288 −4.147
Total QALY 9.290 8.511 0.779
Without inhibitors 6.733 4.161 2.572
With developed inhibitors 2.557 4.350 −1.793
Total direct medical costs (¥) ¥12,060,222 ¥16,638,625 −¥4,578,403
Without inhibitors ¥9,705,371 ¥11,130,026 −¥1,424,655
With developed inhibitors (successful inhibitor eradication treatment) ¥446,010 ¥1,055,041 −¥609,032
With developed inhibitors (inhibitor eradication treatment failure) ¥1,908,841 ¥4,453,557 −¥2,544,717
ICER for rAHF-PFM vs BAY 81-8973 −¥5,875,939

ICER incremental cost-effectiveness ratio, QALY quality-adjusted life years

One-Way Sensitivity Analysis for the Cost Effectiveness

According to the OWSA, the ICER per gained QALY for rAHF-PFM relative to BAY 81-8973 remained negative, irrespective of the changes of model inputs. The model inputs with substantial uncertainty driving the cost effectiveness of rAHF-PFM included annual discounting rate for both health benefits and costs, ABR of rAHF-PFM and BAY 81-8973, quality-of-life utility for patients without the occurrence of any bleeding episodes, and reduced quality of life utility for increasing ABR by one unit. The result of the OWSA is illustrated in Figure 2.

Fig. 2.

Fig. 2

The impact of uncertainty of model variables on the ICER for rAHF-PFM relative to BAY 81-8973 in previously untreated Chinese patients with severe hemophilia A in the one-way sensitivity analysis. FVIII factor VIII, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year

Probabilistic Sensitivity Analysis

The distribution of the generated ICER for the cost effectiveness of rAHF-PFM relative to BAY 81-8973 from Monte Carlo simulations with 5000 iterations was plotted to identify the median value (−¥6,233,459) and 95% credible interval (−¥43,653,389 to ¥2,161,041). Based on the distribution of ICER, prophylactic treatment with rAHF-PFM for PUPs with severe hemophilia A had a 97.5% probability of being cost effective when compared with BAY 81-8973 at a willingness-to-pay threshold of ¥0 per QALY gained. The ICER scatter plot of the generated 5000 ICERs is illustrated in Figure 3.

Fig. 3.

Fig. 3

The scatter plot of the incremental costs and incremental QALY for rAHF-PFM relative to BAY 81-8973 in previously untreated Chinese patients with severe hemophilia A from 5000 Monte Carlo simulations in the probabilistic sensitivity analysis. QALY quality-adjusted life year

Scenario Analysis Results

The results of the scenario analyses were consistent with the base-case findings, confirming the robustness of the model's conclusions across different time horizons. In all scenarios (5, 10, and 20 years), prophylactic treatment with rAHF-PFM remained the cost-effective strategy, providing both greater health benefits (QALYs) and lower total direct medical costs compared with BAY 81-8973.

Specifically, over a 20-year horizon, rAHF-PFM was associated with a gain of 0.734 QALYs and a cost saving of ¥2,948,681. The detailed outcomes for all tested time horizons are presented in Supplementary Table S8, ESM.

Discussion

To our knowledge, the Markov model in our study could be the most comprehensive cost-effectiveness model fully considering the potential impact of inhibitor development of prophylactic treatments with rFVIII on long-term health outcomes and medical costs in patients with severe hemophilia A. By simulating two rFVIII with substantial differences in the incidence of inhibitor development, our study clearly demonstrated that a lower incidence of inhibitor development could result in fewer bleeding episodes. Bleeding episodes substantially reduce quality of life and increase medical costs for on-demand therapy. The attractive cost effectiveness of prophylactic treatment with rAHF-PFM over BAY 81-8973 in our study was likely due to the effectiveness of rAHF-PFM in bleeding control and the lower risk of inhibitor development.

Our study selected two rFVIIIs, rAHF-PFM and BAY 81-8973, that have sufficient literature evidence reporting explaining their substantial difference in the risk of inhibitor development [9, 10, 22]. Even though both rFVIIIs are full length and are manufactured in a plasma-free cell culture environment, their production cell lines differ. rAHF-PFM is produced using CHO cells while BAY 81-8973 is generated from modified BHK cells with the gene for HSP70. This distinction is critical, as the host cell line determines the protein’s post-translational modifications, such as glycosylation, which can impact immunogenicity [7, 8]. This difference in manufacturing provides a plausible molecular explanation for the lower inhibitor risk observed with rAHF-PFM in our analysis. With the substantial differences in the incidence of inhibitor development (30.3% vs 54.8%) and distribution of HTI (55.3% vs 73.9%) between rAHF-PFM and BAY 81-8973 in PUPs with severe hemophilia A, this study simulated and explored how inhibitor development affects long-term health outcomes, medical costs, and the overall cost effectiveness of rFVIII in PUPs with severe hemophilia A. Understanding this impact is an important consideration for both clinical and reimbursement decision making.

Of the patients with developed inhibitors from prophylactic treatment with rFVIIIs, HTI is the major clinical challenge due to a lower success rate for inhibitor eradication than LTI (78.5% vs 94.6%) [41–51]. The patients who fail with inhibitor eradication treatments need to receive expensive prophylactic treatments with emicizumab or on-demand therapy with bypassing agents. Due to the high drug acquisition costs of emicizumab, about 90% of patients without successful inhibitor eradication treatments are unable to afford prophylactic treatments with emicizumab but require on-demand therapy with bypassing agents to manage bleed episodes, which increased by almost 10 times when compared with those receiving emicizumab for prophylactic treatment [52–55]. Thus, unsuccessful inhibitor eradication treatment in patients with HTI can drive up the number of bleed episodes, necessitating on-demand therapy with bypassing agents. In our cost-effectiveness analysis, the clinical outcome acts as the main linkage between inhibitor development and the final model outputs for QALYs and medical costs.

Bleed episodes played a critical role in our cost-effectiveness analysis as they had strong correlations with quality of life, the risks of bleeding-related complications, and medical costs for on-demand therapy. It is challenging to assess the impact of cumulative bleed episodes over time on quality of life, and the current evidence only allowed this study to use a simplified method to estimate quality of life through ABR. Thus, the impact of bleed episodes on quality of life in our study should be underestimated, which can result in the underestimated cost effectiveness of rAHF-PFM. Similarly, our cost-effectiveness model simulated the risk of bleeding-related complications according to ABR as well. This could substantially underestimate the risk of bleeding-related complications associated with inhibitor development and further underestimate the differences in the lifetime cumulative risks of bleeding-related complications between rAHF-PFM and BAY 81-8973. In addition to its lower immunogenicity, the pooled clinical evidence from a systematic literature review in our study indicated that prophylactic treatment with rAHF-PFM was associated with a lower risk of bleeding than BAY 81-8973 in PUPs with severe hemophilia A. According to the model simulations, the cumulative bleed episodes associated with rAHF-PFM were reduced by over 40% when compared with BAY 81-8973. These reduced bleeding episodes made a major contribution to the cost effectiveness of rAHF-PFM over BAY 81-8973 by saving medical costs and gaining more health benefits.

Even though our study constructed a comprehensive cost-effectiveness model simulating most clinical scenarios associated with prophylactic treatments with rFVIIIs in PUPs with severe hemophilia A, the reported clinical and economic impact of inhibitor development in our study should be interpreted with awareness of the following limitations. First, our study assumed lifetime prophylactic treatment with the same rFVIII in the model cohort to assess the impact of inhibitor developments on long-term health outcomes and medical costs. Our model did not consider a treatment switch that could have a substantial impact on the cumulative number of bleeding episodes in the cost-effectiveness analysis. Second, our model inputs for the risk of inhibitor development and treatment effects associated with the two rFVIII were estimated from a limited number of clinical studies with small sample sizes. In addition, there was no adjusted comparisons of the two rFVIII for the clinical outcomes that could substantially affect the model outputs. Thus, future head-to-head comparisons of the profiles of inhibitor development and the direct effects of prophylactic treatment with the two rFVIII on bleeding are still needed to confirm the key model inputs in the cost-effectiveness analysis. Thus, the attractive cost effectiveness of rAHF-PFM over BAY 81-8973 in our study was the result of a conservative assessment. Third, the source studies for the incidence of inhibitor development associated with the two rFVIII included mixed patients with PUP and minimally treated patients (MTP). As MTP have a higher risk of inhibitor development compared with PUP associated with rAHF-PFM [22], the incidence of inhibitor development associated with the two rFVIII products in PUP could be overestimated. Therefore, future studies are still needed to clarify the difference in the incidence of inhibitor development between rAHF-PFM and BAY 81-8973 in PUP. Finally, most model outputs for treatment patterns regarding inhibitor eradication treatments and medical costs were estimated from the survey of five clinical experts. The generalizability of these model inputs could be highly limited and require future real-world research to confirm.

Conclusion

In this study we leveraged the existing literature evidence and constructed a comprehensive cost-effectiveness model to simulate the risk of inhibitor development, inhibitor eradication treatment, and treatment effects of prophylactic treatments with two rFVIII (rAHF-PFM vs BAY 81-8973) with substantially different inhibitor profiles over a lifetime in PUPs with severe hemophilia A. The cost-effectiveness analysis suggested that the rFVIII with lower risk of inhibitor development (rAHF-PFM) resulted in fewer bleeding episodes, which drives the cost effectiveness of rAHF-PFM relative to BAY 81-8973. Future real-world studies with large sample sizes are needed to confirm the key model inputs in the cost-effectiveness analysis model.

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgments

Medical writing support for the development of this manuscript under the direction of the authors was provided by Qianyi Gong, MSc and Wendong Chen, PhD of Changsha Normin Health Technology Ltd and funded by Takeda (China) International Trade Co., Ltd.

Funding

The study was funded by Takeda (China) International Trading Co., Ltd.

Declarations

Conflict of Interest

Congling Gu and Zhenguo Wang are employees of Takeda (China). Congling Gu holds Takeda stock. Other authors have none to declare.

Availability of Data and Material

The data supporting the findings of this study are derived from publicly available literature and expert interviews. No individual patient data were used in this study. The literature data can be accessed from the respective publications, and expert interview aggregated data are available from the corresponding author on reasonable request.

Ethical Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Code Availability

The Excel-based model used to conduct this analysis contains proprietary information and is not publicly available.

Author Contributions

Li Yang, Jie Peng, Congling Gu, Zhenguo Wang, and Genyong Zuo formulated the research idea and developed the study protocol. Genyong Zuo, Li Yang and Congling Gu constructed the model structure and completed the model analysis. Congling Gu and Zhenguo Wang estimated the model variables. Li Yang, Jie Peng, Congling Gu, Zhenguo Wang, and Genyong Zuo were fully involved with the development of this manuscript. All authors critically reviewed the manuscript and approved the submission of this manuscript.

References

  • 1.Song X, Zhong J, Xue F, et al. An overview of patients with haemophilia A in China: epidemiology, disease severity and treatment strategies. Haemophilia. 2021;27(1):e51–9. 10.1111/hae.14217. [DOI] [PubMed] [Google Scholar]
  • 2.Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol. 2012;81(1):82–93. 10.1016/j.critrevonc.2011.01.002. [DOI] [PubMed] [Google Scholar]
  • 3.Blatny J, Komrska V, Blazek B, Penka M, Ovesna P, Czech National Haemophilia Programme. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003. Blood Coagul Fibrinolysis. 2015;26(6):673–8. 10.1097/MBC.0000000000000298. [DOI] [PubMed] [Google Scholar]
  • 4.Fijnvandraat K, Bril WS, Voorberg J. Immunobiology of inhibitor development in hemophilia A. Semin Thromb Hemost. 2003;29(1):61–8. 10.1055/s-2003-37940. [DOI] [PubMed] [Google Scholar]
  • 5.Carcao M, Mancuso ME, Young G, Jiménez-Yuste V. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021;14(2):143–8. 10.1080/17474086.2021.1875817. [DOI] [PubMed] [Google Scholar]
  • 6.Peyvandi F, Miri S, Garagiola I. Immune responses to plasma-derived versus recombinant FVIII products. Front Immunol. 2021;11:591878. 10.3389/fimmu.2020.591878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Qu J, Ma C, Xu XQ, et al. Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII. PLoS ONE. 2020;15(5):e0233576. 10.1371/journal.pone.0233576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lai JD, Swystun LL, Cartier D, et al. N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice. Haematologica. 2018;103(11):1925–36. 10.3324/haematol.2018.188219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Jardim LL, Santana MP, Chaves DG, et al. Risk factors for antibody formation in children with hemophilia: methodological aspects and clinical characteristics of the HEMFIL cohort study. Blood Coagul Fibrinolysis. 2021;32(7):443–50. 10.1097/MBC.0000000000001057. [DOI] [PubMed] [Google Scholar]
  • 10.Ljung R, Chan AKC, Glosli H, et al. BAY 81–8973 efficacy and safety in previously untreated and minimally treated children with severe hemophilia A: the LEOPOLD kids trial. Thromb Haemost. 2023;123(1):27–39. 10.1055/s-0042-1757876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017;6(4):46. 10.3390/jcm6040046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Woods B, Sideris E, Palmer S, Sculpher M, Claxton K. Partitioned survival analysis for decision modelling in health care: a critical review. NIHR DSU Technical Support Document 14. 2013. http://www.nicedsu.org.uk.
  • 13.Zhang T, Chen X, Li C, et al. Cost-effectiveness analysis of risk factor-based lung cancer screening program by low-dose computer tomography in current smokers in China. Cancers (Basel). 2023;15(18):4445. 10.3390/cancers15184445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 15.Musso R, Santagostino E, Faradji A, et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost. 2008;99(1):52–8. 10.1160/TH07-06-0409. [DOI] [PubMed] [Google Scholar]
  • 16.Yang QD, Niu Q, Zhou YH, et al. Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000. Cerebrovasc Dis. 2004;17(4):303–13. 10.1159/000077341. [DOI] [PubMed] [Google Scholar]
  • 17.Xu RH, Dong D, Luo N, et al. Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia. Eur J Health Econ. 2021;22(4):547–57. 10.3390/10.1007/s10198-021-01273-5. [DOI] [PubMed] [Google Scholar]
  • 18.Young L, Chen Y, Alvir J, et al. The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study. Orphanet J Rare Dis. 2023;18(1):227. 10.1186/s13023-023-02690-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014. [PubMed] [Google Scholar]
  • 20.Yaozhi Data. Yaozhi Database. Chongqing (China): Yaozhi Data Technology Co., Ltd; 2024 [cited 2024 May]. https://db.yaozh.com/.
  • 21.Briggs AH, Weinstein MC, Fenwick EAL, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force–7. Med Decis Mak. 2012;32(5):722–32. 10.1177/0272989X12458348. [DOI] [PubMed] [Google Scholar]
  • 22.Auerswald G, Kurnik K, Aledort LM, et al. The EPIC study: a lesson to learn. Haemophilia. 2015;21(5):622–8. 10.1111/hae.12666. [DOI] [PubMed] [Google Scholar]
  • 23.Peyvandi F, Cannavò A, Garagiola I, et al. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018;16(1):39–43. 10.1111/jth.13888. [DOI] [PubMed] [Google Scholar]
  • 24.Taki M, Hanabusa H, Fukutake K, et al. Real-life clinical experience of 117 previously untreated patients (PUPs) treated with antihemophilic factor (recombinant), plasma/albumin free method in a Japanese post-authorization safety study. Haemophilia. 2014;20:18. 10.1111/hae.12400. [Google Scholar]
  • 25.Calvez T, Chambost H, Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398–408. 10.1182/blood-2014-07-586347. [DOI] [PubMed] [Google Scholar]
  • 26.Auerswald G, Thompson AA, Recht M, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012;107(6):1072–82. 10.1160/TH11-09-0642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Calvez T, Chambost H, d’Oiron R, et al. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica. 2018;103(1):179–89. 10.3324/haematol.2017.174706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Collins PW, Palmer BP, Chalmers EA, et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood. 2014;124(23):3389–97. 10.1182/blood-2014-07-580498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Prezotti ANL, Cerqueira MH, Renni M, et al. Incidence of inhibitors in a previously untreated patients with severe hemophilia a cohort treated with a single third-generation recombinant factor VIII concentrate. Blood. 2018. 10.1182/blood-2018-99-119754. [Google Scholar]
  • 30.Jardim LL, Antônio Portugal Santana M, Gonçalves Chaves D, et al. Clinical characteristics and incidence of inhibitors in previously untreated children with haemophilia: an update of the hemfil cohort study. Res Pract Thromb Haemost. 2021. 10.1002/rth2.12589. [Google Scholar]
  • 31.Olivieri M, Simpson M, Yan S, et al. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A. Curr Med Res Opin. 2022;38(7):1133–9. 10.1080/03007995.2022.2062180. [DOI] [PubMed] [Google Scholar]
  • 32.Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6(8):1319–26. 10.1111/j.1538-7836.2008.03032.x. [DOI] [PubMed] [Google Scholar]
  • 33.Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359–67. 10.1111/j.1538-7836.2011.04611.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Tsakiris DA, Oldenburg J, Klamroth R, et al. Effectiveness and safety outcomes in patients with hemophilia a receiving antihemophilic factor (recombinant) for at least 5 years in a real-world setting: 6-year interim analysis of the ahead international and German studies. Blood. 2020;136:1. 10.1182/blood-2020-139873.32430499 [Google Scholar]
  • 35.Mahlangu JN, Kavakli K, Hvitfeldt Poulsen L, et al. Prophylactic efficacy of twice-weekly vs. 3-timesweekly bay 81-8973 in severe hemophilia A: Results of the Leopold I and II clinical trials. J Thromb Haemost. 2015;13:858. 10.1111/jth.12993
  • 36.Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360–9. 10.1111/jth.12828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and safety of BAY 81–8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016;22(5):706–12. 10.1111/hae.12952. [DOI] [PubMed] [Google Scholar]
  • 38.Mahlangu J, Lopez Fernandez MF, Santagostino E, et al. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years. Eur J Haematol. 2020;104(6):594–601. 10.1111/ejh.13402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Chowdary P, Fischer K, Collins PW, et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis. Thromb Haemost. 2020;120(5):728–36. 10.1055/s-0040-1709519. [DOI] [PubMed] [Google Scholar]
  • 40.Khair K, Mazzucconi MG, Parra R, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Haemophilia. 2018;24(1):85–96. 10.1111/hae.13361. [DOI] [PubMed] [Google Scholar]
  • 41.Nogami K, Taki M, Matsushita T, et al. The Japanese Immune Tolerance Induction (J-ITI) study in haemophilia patients with inhibitor: outcomes and successful predictors of ITI treatment. Haemophilia. 2018;24(5):e328–37. 10.1111/hae.13531. [DOI] [PubMed] [Google Scholar]
  • 42.Wang C, Liu G, Ding Y, et al. Application of peripherally inserted central catheter in immune tolerance induction treatment of children with hemophilia A and accompanying inhibitors in China. Hematology (Amsterdam, Netherlands). 2023;28(1):2250601. 10.1080/16078454.2023.2250601. [DOI] [PubMed] [Google Scholar]
  • 43.Elalfy M, Elghamry I, Hassab H, et al. Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success. Haemophilia. 2022;28(1):65–72. 10.1111/hae.14456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Li Z, Chen Z, Cheng X, et al. Successful inhibitor eradication for hemophilia A children with poor-risk high-titer inhibitor using low-dose immune tolerance induction strategy. Res Pract Thromb Haemost. 2020;4(SUPPL 1):544–5. 10.1002/rth2.12393. [Google Scholar]
  • 45.Prezotti ANL, Ferreira C, Oliveira L, et al. Evaluation of predictors of outcome in immune tolerance induction treatment of hemophilia αpatients with high-responding inhibitors. Blood. 2017. 10.1182/blood.V130.Suppl_1.2357.2357. [Google Scholar]
  • 46.Ryu JE, Park YS, Yoo KY, et al. Immune tolerance induction in patients with severe hemophilia A with inhibitors. Blood Res. 2015;50(4):248–53. 10.5045/br.2015.50.4.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Sun J, Li Z, Li G, et al. Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors. Thromb Res. 2023;226:56–60. 10.1016/j.thromres.2023.04.002. [DOI] [PubMed] [Google Scholar]
  • 48.Camelo RM, Dias MM, Caram-Deelder C, et al. Time between inhibitor detection and start of immune tolerance induction: association with outcome in the BrazIT study. J Thromb Haemost. 2022;20(11):2526–37. 10.1111/jth.15878. [DOI] [PubMed] [Google Scholar]
  • 49.Nik Mohd Salim NN. Immune tolerance induction in paediatric patients with severe Haemophilia A with inhibitors: Malaysian experience. Haemophilia. 2020;26:33. 10.1111/hae.13941.31742871 [Google Scholar]
  • 50.Rivard GE, Rothschild C, Toll T, et al. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study. Haemophilia. 2013;19(3):449–55. 10.1111/hae.12102. [DOI] [PubMed] [Google Scholar]
  • 51.Zulfikar B, Koc B, Ozdemir N. Low-dose immune tolerance induction in hemophilia: a single-center experience. J Pediatr Hematol Oncol. 2019;41(6):e355–8. 10.1097/MPH.0000000000001391. [DOI] [PubMed] [Google Scholar]
  • 52.Oldenburg J, Shima M, Kruse-Jarres R, et al. Outcomes in children with hemophilia A with inhibitors: results from a noninterventional study. Pediatr Blood Cancer. 2020;67(10):e28474. 10.1002/pbc.28474. [DOI] [PubMed] [Google Scholar]
  • 53.Mancuso ME, Callaghan MU, Kruse-Jarres R, et al. Emicizumab prophylaxis in adolescent/adult patients with hemophilia a previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the haven 1 study. Blood. 2017. 10.1182/blood.V130.Suppl_1.1071.1071. [Google Scholar]
  • 54.Wall C, Xiang H, Palmer B, et al. Real world efficacy of emicizumab in haemophilia a with inhibitors: a report from the UK national haemophilia database. Res Pract Thromb Haemost. 2020;4(SUPPL 1):462. 10.1002/rth2.12393. [Google Scholar]
  • 55.Poon MC, Lee A, Germini F, et al. Real-world outcomes of emicizumab in hemophilia A with or without FVIII inhibitors from the Canadian Hemophilia Bleeding Disorder Registry. Blood. 2022;140:8465–7. 10.1182/blood-2022-157531. [Google Scholar]
  • 56.Shapiro AD, Fernandez A, Teitel J, et al. Final results of the prospective ADVATE® immune tolerance induction registry (PAIR) study with plasma- and albumin-free recombinant factor VIII. J Blood Med. 2021;12:991–1001. 10.2147/JBM.S329883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127–38. 10.1182/blood.2019001869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Callaghan M, Negrier C, Paz-Priel I, et al. Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia a (PWHA) with or without FVIII inhibitors: pooled data from four haven studies. Res Pract Thromb Haemost. 2019;3:116. 10.1002/rth2.12227. [Google Scholar]
  • 59.Ettingshausen CE, Hermans C, Holme PA, et al. Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA global outcome (FEIBA GO) study. Ther Adv Hematol. 2023;14:20406207231184323. 10.1177/20406207231184323. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from PharmacoEconomics Open are provided here courtesy of Springer

RESOURCES